You are here

Phase 2 Trial of SGN-30 Initiated, Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma

BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 23, 2004--Seattle Genetics, Inc. (Nasdaq:SGEN - News) announced today that it has initiated a phase II clinical trial of SGN-30 for the treatment of primary cutaneous anaplastic large cell lymphoma (ALCL). Primary cutaneous ALCL, which is a type of non-Hodgkin's lymphoma that involves the skin, is the company's third clinical indication for SGN-30. The phase II study is designed to evaluate the antitumor activity and tolerability of SGN-30 in up to 40 patients who have relapsed or are resistant to prior therapies.

Seattle Genetics is conducting additional phase II studies of SGN-30 in Hodgkin's disease and systemic ALCL. The company has reported data from the first five systemic ALCL patients treated with SGN-30, noting that objective responses were observed in two patients. Seattle Genetics plans to report additional preliminary data from these ongoing phase II studies at the American Society for Hematology (ASH) Annual Meeting in December 2004.

"We are optimistic about the therapeutic potential of SGN-30 in ALCL and believe it may offer a rapid path to regulatory approval," stated Dr. Michael McDonald, Chief Medical Officer of Seattle Genetics. "We are also conducting clinical trials of SGN-30 in Hodgkin's disease as a single agent and are planning future studies in combination with chemotherapy."

SGN-30 is a genetically engineered monoclonal antibody that targets CD30-positive hematologic malignancies, including Hodgkin's disease and certain types of lymphomas and leukemias. The company has received orphan drug designations from the FDA for SGN-30 in both Hodgkin's disease and T-cell lymphomas, a category that includes ALCL. Seattle Genetics is also conducting preclinical studies to evaluate the potential of SGN-30 in the treatment of immunologic diseases.

About ALCL
Anaplastic large cell lymphoma (ALCL) is a type of T-cell non-Hodgkin's lymphoma. According to the American Cancer Society, approximately 54,300 new cases of non-Hodgkin's lymphoma, of which an estimated 15% are of T-cell origin, will be diagnosed in the United States during 2004. Most ALCL cases fall into one of two distinct forms: systemic ALCL, involving lymph nodes or extranodal sites; or primary cutaneous ALCL, involving skin nodules. For more information about ALCL, visit

Source: Seattle Genetics, Inc.

Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy